Chemo only: Patients who only used chemotherapy during neodajuvant treatment period
Immunochemotherapy: Patients who used immunotherapy combined with chemotherapy during neodajuvant treatment period
Study summary
This study is a single-center, retrospective cohort study. The purpose is to evaluate different perioperative treatment options on the efficacy and survival prognosis of locally advanced GC/GEJC, clarify whether the tumor regression grade can influence survival of patients using neoadjuvant therapy. Moreover, we aim to explore the clinical and pathological characteristics that will affect the long-term survival benefit of patients who underwent perioperative treatment.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* (1) Pathologically diagnosed as gastric adenocarcinoma or esophageal-gastric junction adenocarcinoma, and has not received any anti-tumor treatment before (such as surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.)
* (2) cT3-4N+M0 (according to AJCC version 8 stage) confirmed as resectable by CT or MRI.
* (3) Patients who underwent adjuvant therapy before surgery.
* (4) After neoadjuvant therapy , radical resection was performed at the Cancer Hospital of the Chinese Academy of Medical Sciences.
* (5) Patients who have complete clinical, pathological and imaging data.
Exclusion Criteria:
* (1) It is known that peritoneal metastasis or peritoneal irrigation solution cytology is positive (CY1P0) or there is distant metastasis (according to the 8th edition of AJCC).
* (2) There are unresectable factors, including irresectable tumor causes or surgical contraindications that are irresectable or refuse surgery.
* (3) Those who have suffered from other malignant tumors within 5 years or at the same time, except for cured skin basal cell carcinoma and cervical cancer in situ and breast cancer in situ.
* (4) Those who have had radiotherapy, interventional treatment and other local therapists before surgery.
* (5) Patients whose key diagnosis and treatment information records were missing.
Primary outcome measure(s)
OS — From the start date of cycle 1 (each cycle is 14 days or 21 days) neoadjuvant therapy until the date of first documented death from any cause, assessed up to 100 months. overall survival
Trial sites (1)
Facility
City
Region
Status
Cancer Hodpital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing
Beijing Municipality
More Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.